What's Going On With Polaryx Therapeutics Stock Wednesday?

Benzinga

02/18

Polaryx Therapeutics Inc. (NASDAQ:PLYX) stock tumbled Wednesday, giving back gains after a sharp one-day surge sparked by a major clinical development announcement on Tuesday. The stock closed Tuesday...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2612813442"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612813442\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612813442?lang=zh_TW&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/18/Defense--Biotech-Favored.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2026-02-18 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612813442","market":"us","top_or_hot":-1,"title":"What's Going On With Polaryx Therapeutics Stock Wednesday?","media":"Benzinga","content":"<div>\n<p>Polaryx Therapeutics Inc. (NASDAQ:PLYX) stock tumbled Wednesday, giving back gains after a sharp one-day surge sparked by a major clinical development announcement on Tuesday.\nThe stock closed Tuesday...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50689541/whats-going-on-with-polaryx-therapeutics-stock-wednesday\">网页链接</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Polaryx Therapeutics Stock Wednesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Polaryx Therapeutics Stock Wednesday?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2026-02-18 23:19</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Polaryx Therapeutics Inc. (NASDAQ:PLYX) stock tumbled Wednesday, giving back gains after a sharp one-day surge sparked by a major clinical development announcement on Tuesday.\nThe stock closed Tuesday...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50689541/whats-going-on-with-polaryx-therapeutics-stock-wednesday\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50689541/whats-going-on-with-polaryx-therapeutics-stock-wednesday\">Benzinga</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50689541/whats-going-on-with-polaryx-therapeutics-stock-wednesday","article_id":"2612813442","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/18/Defense--Biotech-Favored.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50689541/whats-going-on-with-polaryx-therapeutics-stock-wednesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612813442","pubTimestamp":1771427940,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Polaryx Therapeutics Inc.  stock tumbled Wednesday, giving back gains after a sharp one-day surge sparked by a major clinical development announcement on Tuesday.The stock closed Tuesday up 64.32% at $3.96, after the company announced it had selected a contract research organization  for its SOTERIA Phase 2 basket trial.The trial is designed to evaluate PLX-200, Polaryx’s lead candidate, across multiple lysosomal storage disorders.Polaryx said the CRO selection marks a pivotal milestone as it prepares to initiate the trial in the first half of 2026. The trial will assess the safety, tolerability, and clinical activity of PLX-200 across four different lysosomal storage disorders.Polaryx previously received a safe-to-proceed letter from the FDA in October 2025. The SOTERIA trial will incorporate natural history data as a control arm compared to the PLX-200 treated arm.PLX-200 is an orally available compound derived from gemfibrozil. The company noted that compelling clinical activity cou","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PLYX":"Polaryx Therapeutics Inc"},"translate_title":"Polaryx Therapeutics股票周三发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLYX":1.5},"content_text":"Polaryx Therapeutics Inc. (NASDAQ:PLYX) stock tumbled Wednesday, giving back gains after a sharp one-day surge sparked by a major clinical development announcement on Tuesday.\nThe stock closed Tuesday up 64.32% at $3.96, after the company announced it had selected a contract research organization (CRO) for its SOTERIA Phase 2 basket trial. \nThe trial is designed to evaluate PLX-200, Polaryx’s lead candidate, across multiple lysosomal storage disorders.\nPolaryx said the CRO selection marks a pivotal milestone as it prepares to initiate the trial in the first half of 2026. The trial will assess the safety, tolerability, and clinical activity of PLX-200 across four different lysosomal storage disorders.\nPolaryx previously received a safe-to-proceed letter from the FDA in October 2025. The SOTERIA trial will incorporate natural history data as a control arm compared to the PLX-200 treated arm. \nPLX-200 is an orally available compound derived from gemfibrozil. The company noted that compelling clinical activity could potentially lead to conditional marketing authorization.\nDespite Tuesday’s surge, PLYX has declined 88.69% over the past 12 months and remains considerably closer to its 52-week low of $2.20 than its 52-week high of $48.91.\nPLYX Price Action: Polaryx Therapeutics shares were down 22.47% at $3.07 at the time of publication on Wednesday, according to Benzinga Pro data.\nPhoto by PeopleImages.com – Yuri A via Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}